KR20250019030A - Rock2 억제제 - Google Patents

Rock2 억제제 Download PDF

Info

Publication number
KR20250019030A
KR20250019030A KR1020247038811A KR20247038811A KR20250019030A KR 20250019030 A KR20250019030 A KR 20250019030A KR 1020247038811 A KR1020247038811 A KR 1020247038811A KR 20247038811 A KR20247038811 A KR 20247038811A KR 20250019030 A KR20250019030 A KR 20250019030A
Authority
KR
South Korea
Prior art keywords
alkyl
group
alkynyl
alkenyl
cycloalkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020247038811A
Other languages
English (en)
Korean (ko)
Inventor
사무엘 디. 왁살
알렉산드라 자닌-조로프
게오르기 카츠코프스키
막달레나 솔루치
안나 예드제이츠작
마틴 클바나
도미니크 도마가라
Original Assignee
그래비톤 바이오사이언스 비브이
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 그래비톤 바이오사이언스 비브이 filed Critical 그래비톤 바이오사이언스 비브이
Publication of KR20250019030A publication Critical patent/KR20250019030A/ko
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Neurosurgery (AREA)
  • Pulmonology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
KR1020247038811A 2022-04-29 2023-04-29 Rock2 억제제 Pending KR20250019030A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202263336667P 2022-04-29 2022-04-29
US63/336,667 2022-04-29
PCT/IB2023/054494 WO2023209692A1 (en) 2022-04-29 2023-04-29 Inhibitors of rock2

Publications (1)

Publication Number Publication Date
KR20250019030A true KR20250019030A (ko) 2025-02-07

Family

ID=86604437

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020247038811A Pending KR20250019030A (ko) 2022-04-29 2023-04-29 Rock2 억제제

Country Status (9)

Country Link
US (1) US20250289807A1 (enExample)
EP (1) EP4514466A1 (enExample)
JP (1) JP2025514382A (enExample)
KR (1) KR20250019030A (enExample)
CN (1) CN119604496A (enExample)
AU (1) AU2023262720A1 (enExample)
CA (1) CA3250707A1 (enExample)
IL (1) IL316616A (enExample)
WO (1) WO2023209692A1 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2026502949A (ja) 2022-12-30 2026-01-27 アヴィセンナ バイオサイエンシズ インコーポレイテッド アザインドールrock阻害剤
IL327381A (en) 2023-09-28 2026-05-01 Graviton Pharmaceuticals B V Treatment for type 1 diabetes using ROCK2 and DYRK1 inhibitors
IL327385A (en) 2023-09-29 2026-05-01 Graviton Pharmaceuticals B V ROCK2 inhibitors in the treatment of obesity
WO2026011129A1 (en) * 2024-07-03 2026-01-08 Avicenna Biosciences, Inc. Azaindole rock inhibitors for the treatment of medical disorders
CN120204259B (zh) * 2025-04-17 2025-11-18 江西省肿瘤医院(江西省第二人民医院、江西省癌症中心) Rock2抑制剂及其在制备治疗胆管癌的药物中的应用

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7311228B2 (ja) 2017-06-30 2023-07-19 ベイジン タイド ファーマシューティカル カンパニー リミテッド Rho-関連プロテインキナーゼ阻害剤、それを含む医薬組成物並びにその調製方法及び使用
JP7399848B2 (ja) * 2017-09-01 2023-12-18 カドモン コーポレイション,リミティド ライアビリティ カンパニー Rho関連コイルドコイル含有プロテインキナーゼの阻害剤

Also Published As

Publication number Publication date
WO2023209692A1 (en) 2023-11-02
CN119604496A (zh) 2025-03-11
JP2025514382A (ja) 2025-05-02
US20250289807A1 (en) 2025-09-18
CA3250707A1 (en) 2023-11-02
IL316616A (en) 2024-12-01
AU2023262720A1 (en) 2024-12-12
EP4514466A1 (en) 2025-03-05

Similar Documents

Publication Publication Date Title
US20250289807A1 (en) Inhibitors of ROCK2
WO2024110851A1 (en) Inhibitors of rock2
EP3584239B1 (en) O-aminoheteroaryl alkynyl-containing compound, preparation method therefor, and use thereof
CN117143107A (zh) 1,2-二氢吡啶类衍生物及其制备方法和用途
JP2022517723A (ja) Cdk阻害剤としての大環状化合物、その製造方法及びその医薬品における応用
US12240844B2 (en) Pyrrolopyridine derivative and use thereof in prevention and treatment of protein kinase-related disease
JP2020532549A (ja) Rho関連コイルドコイル含有プロテインキナーゼの阻害剤
KR20200090636A (ko) 피롤로피리미딘 유도체 및 이를 유효성분으로 함유하는 단백질 키나아제 관련 질환의 예방 또는 치료용 약학적 조성물
EP3418277B1 (en) Substituted amino six-membered nitric heterocyclic ring compound and preparation and use thereof
CN114437116A (zh) 杂环化合物及其制备方法、药物组合物和应用
CN112979656A (zh) 一类靶向降解btk蛋白的化合物
JP2025509830A (ja) 血液脳関門を通過するmll1-wdr5タンパク質間相互作用阻害剤化合物及びそれらの使用
CN114599655B (zh) 咪唑烷酮类化合物及其制备方法与应用
WO2025223561A1 (zh) 一种喹唑啉酮并五元杂环化合物及其药用组合物和用途
KR102329720B1 (ko) 단백질 키나아제 저해 활성을 갖는 신규한 피리미도[4,5-d]피리미딘-2-온 유도체
KR102329723B1 (ko) 단백질 키나아제 저해 활성을 갖는 신규한 피리미도[4,5-d]피리미딘-2-온 유도체
CN111377906B (zh) 取代的吡嗪化合物及其制备方法和用途
EP4556477A1 (en) Tgf-beta inhibitor compound and use thereof
CN121824539A (zh) 稠环化合物及其制备方法和应用
HK40065338A (en) Pyrrolopyridine derivative and use thereof in prevention and treatment of protein kinase-related disease
HK40076191A (en) Imidazolidinone compound, preparation method therefor and use thereof

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-NAP-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000